Paroxysmal Nocturnal Haemoglobinuria (PNH)
Also known as: Marchiafava-Micheli Syndrome / Paroxysmal Nocturnal Hemoglobinuria / Paroxysmal Nocturnal Hemoglobinuria (PNH) / Paroxysmal Nocturnal Haemoglobinuria / Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli] / Haemoglobinuria: [external cause] or [haemolytic] or [paroxysmal nocturnal] / Paroxysmal nocturnal hemoglobinuria (disorder) / (Haemoglobinuria: [March]) or (Marchiafava-Micheli syndrome)
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB01257 | Eculizumab | A recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). |
| DB16694 | Pegcetacoplan | A complement inhibitor indicated in the treatment of adults with paroxysmal nocturnal hemoglobinuria. |
| DB11580 | Ravulizumab | A monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB01257 | Eculizumab | Complement C5 | target |
| DB16694 | Pegcetacoplan | Complement C3 | target |
| DB11580 | Ravulizumab | Complement C5 | target |